Summary of InMode (INMD) Conference Call - May 19, 2025 Company Overview - InMode is an Israeli-based company specializing in medical aesthetic equipment, particularly surgical equipment that penetrates the skin [2][3] - Established around 16 years ago, with R&D and manufacturing based in Israel [2] - The company went public in February 2019 at $7 per share and has since seen significant revenue growth [8] Financial Performance - Revenue reached approximately $495 million in 2023, up from $22 million in 2017 [5][6] - Experienced a 20% revenue decline in 2024 due to economic slowdown and increased interest rates [10] - Target for 2025 is to match 2024 revenue levels [10] Product and Technology - InMode's technology includes radio frequency-assisted lipolysis and bipolar Matrix RF (Morpheus) [4][6] - The company has diversified its product line to include applications for urinary incontinence, overactive bladder, and facial rejuvenation [6] - Currently has about 12 platforms in its product portfolio, selling in 90 countries [7] Market Dynamics - The U.S. market constitutes 50% of the business, with the rest coming from international markets [19] - The company faces stronger headwinds in the U.S. compared to international markets, with consumer confidence being a significant issue [22][27] - The first quarter is typically the slowest, with Q2 expected to be stronger [30] Operational Challenges - The ongoing conflict in Israel has posed challenges, but the company has managed to maintain operations [12][35] - Tariff exposure is estimated to impact gross margins by 2% to 3% due to most products being manufactured in Israel [38][39] Marketing and Sales Strategy - The company spends heavily on marketing and sales, with a focus on both B2B and B2C strategies [16][60] - Sales and marketing expenses account for 35% to 40% of revenue, while G&A and R&D expenses are relatively low at around 3% and 4%, respectively [59][60] Future Outlook - The company is optimistic about the recovery of the aesthetic procedure market, although it does not expect an immediate surge in demand [99] - Plans to continue product innovation, with new wellness platforms expected to launch later in 2025 [52] - The management is focused on international expansion, establishing subsidiaries in Argentina and Thailand [71][72] Capital Allocation - In the past 12 months, InMode has repurchased $412 million of its stock, totaling $508 million over two years [85][87] - The company is open to various capital allocation strategies, including further buybacks, M&A, and dividends, depending on market conditions [85][86] Key Risks - Economic slowdown and rising interest rates are significant risks affecting consumer spending on aesthetic procedures [10][22] - The company is closely monitoring inflation trends in both the U.S. and Europe [23] Conclusion - InMode remains a leader in the medical aesthetics market, with a strong focus on innovation and international growth despite current economic challenges [11][72]

The Beauty Health Company (SKIN) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Norberto Aja - Investor RelationsMarla Beck - President & CEOMichael Monahan - CFOJonathan Block - Managing DirectorSarah Whitaker Clemente - Director, Healthcare Conference Call Participants None - AnalystSusan Anderson - Managing Director & Senior AnalystBruce Jackson - Senior AnalystNavann Ty - Analyst Operator and welcome to today's Beauty Health Company First Quarter twenty twenty five Earnings Call. At ...

The Beauty Health Company (SKIN) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 and welcome to today's Beauty Health Company First Quarter twenty twenty five Earnings Call. At this time, all participants are in a listen only mode. Later, you will have the opportunity to ask a question during the question and answer session. Please note this call is being recorded and I will be standing by if you should need any assistance. It is now my pleasure to turn the conference over to Norberto Ajah, Investor ...